@Austinmulder95@Helus_Pharma It had some good moves earlier in the year but I think there’s disappointment across the sector that RFK didn’t move on psychedelics like we thought he would.
$DFTX is looking much stronger in the space, even though it does different (and arguably more exciting) compounds